Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results
May 5, 2015 4:05 PM EDTTotal Revenue of $180.0 Million Adjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk Hereditary Cancer Panel Ended Third Quarter at 58 Percent Conversion Myriad Acquires MVZ Clinic to Facilitate Reimbursement in Germany Company Provides Fiscal Fourth-Quarter 2015 Financial Guidance
SALT LAKE CITY, May 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) today announced financial results for its fiscal third-quarter and nine months ended March 31, 2015, provided an update on recent business highlights and provided fiscal fourth-quarter... More
